The pathological significance of aberrant glycosylation is particularly evident in MS, where modifications in mannose trigger inflammatory responses through activation of the mannose-binding lectins (MBLs) complement pathway, an innate immune pathway that recognizes foreign pathogens. Here, MBL2 is linked to myeloid sarcoma.